Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1244]

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Gemcitabine, cisplatin plus nivolumab achieves clinical complete response in subset of muscle-invasive bladder cancer patients ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial...

Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection ( Prof Matt Galsky - Icahn School of Medicine at Mount Sinai, New York City, USA )

Hypofractionated high dose intensity modulated radiotherapy non-inferior for...

Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK

$Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer ( Prof Joe M O'Sullivan - Queen's University Belfast, Belfast, UK )$

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for...

Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma ( Dr Srikala Sridhar - Princess Margaret Cancer Centre, Ontario, Canada )

Stereotactic body radiotherapy compared with surgery for localised prostate...

Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK

Stereotactic body radiotherapy compared with surgery for localised prostate cancer ( Dr Nicholas John van As - The Royal Marsden NHS Foundation Trust, London, UK )

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer

Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )

Choosing Wisely in haemato oncology and medical oncology

Dr Omar Hamid - Garissa Cancer Center, Garissa, Kenya

Choosing Wisely in haemato oncology and medical oncology ( Dr Omar Hamid - Garissa Cancer Center, Garissa, Kenya )

Choosing Wisely in haemato-medical oncology

Dr Omar Hamid - Garissa Cancer Centre, Garissa, Kenya

Choosing Wisely in haemato-medical oncology ( Dr Omar Hamid - Garissa Cancer Centre, Garissa, Kenya )

Choosing Wisely campaigns in Africa

Dr Fidel Rubagumya - Rwanda Military Hospital, Kigali, Rwanda

Choosing Wisely campaigns in Africa ( Dr Fidel Rubagumya - Rwanda Military Hospital, Kigali, Rwanda )

Lessons learned from Choosing Wisely campaigns in Africa

Dr Fidel Rubagumya - Rwanda Military Hospital, Kigali, Rwanda

Lessons learned from Choosing Wisely campaigns in Africa ( Dr Fidel Rubagumya - Rwanda Military Hospital, Kigali, Rwanda )

The Choosing Wisely Brazil oncology task force

Dr Fabio Moraes - Queen's University, Kingston, Canada

The Choosing Wisely Brazil oncology task force ( Dr Fabio Moraes - Queen's University, Kingston, Canada )

Lessons learned from Choosing Wisely in Brazil

Dr Fabio Moraes - Queen's University, Kingston, Canada

Lessons learned from Choosing Wisely in Brazil ( Dr Fabio Moraes - Queen's University, Kingston, Canada )

More from ecancer